Publicação científica trimestral do CREMERJ - número 4 - 2022

72 Atualização em Câncer de Mama Maurício Magalhães Costa Med. Ciên. e Arte , Rio de Janeiro, v.1, n.4, p.55-73, out-dez 2022 REFERÊNCIAS 1. R Sherman, R Firth, M Charlton, et al., eds. Cancer in North America: 2014-2018. Volume One: Combined Cancer Incidence for the United States, Canada and North America. North American Association of Central Cancer Registries, Inc; 2021. 2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Canc. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6. PMID: 30350310. 3. Brasil. Ministério da Saúde. Informações de saúde: TABNET. Demográficas e socioeconômicas. Brasília, DF: Ministério da Saúde, c2008a. Disponível em: http://www.datasus.gov.br/DATASUS/index. php?area=0206&id=6942. Acesso em: 11 set. 2019. 4. Brasil. Ministério da Saúde. SIM: Sistema de informações sobre mortalidade. Brasília, DF: Ministério da Saúde, c2008b. Disponível em: http://www.datasus.gov.br . Acesso em: 5 set. 2019. 5. Honma N, Matsuda Y, Mikami T. Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones. Cancers (Basel). 2021 May 25;13(11):2588. doi: 10.3390/cancers13112588. 6. Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. Biomed Res Int. 2022 Apr 18;2022:9605439. doi: 10.1155/2022/9605439. eCollection 2022. 7. Rocco N, Montagna G, Criscitiello C, Nava MB, Privitera F, Taher W, Gloria A, Catanuto G. Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. Genes (Basel). 2021 Feb 10;12(2):253. doi: 10.3390/genes12020253. 8. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017;377:2228-39. 9. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-427. Doi: 10.1016/s0140-6736(03) 14065-2 10. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168. 11. Bhardwaj, Brown KA Obese Adipose Tissue as a Driver of Breast Cancer Growth and Development: Update and Emerging Evidence. Front Oncol. 2021 Mar 30;11:638918. doi: 10.3389/fonc.2021.638918. eCollection 2021. 12. Yu P, Guo S, Xu R, Ye T, Li S, Sim MR, Abramson MJ, Guo Y.Cohort studies of long-term exposure to outdoor particulate matter and risks of cancer: A systematic review and meta-analysis.Innovation (N Y). 2021 Jul 13;2(3):100143. doi: 10.1016/j.xinn.2021.100143. eCollection 2021 Aug 28. 13. International Menopause Society. Comment on: Type and timing of menopausal hormone therapy and breast cancer risk: individual participant metaanalysis of the worldwide epidemiological evidence [Internet]. 2019 [cited 2020 Mar 22]. Disponível em: https://www.imsociety.org/manage/images/ pdf/5054afeb9b1bc763032333443f1c0bed.pdf 14. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet 2014; 383(9922): 1041-1048. 15. Eisen A, Lubinski J, Klijn J, et al. Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case Control Study. J Clin Oncol 2005; 23:30, 7491-7496. 16. Valero MG, Moo TA, Muhsen S, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini V Use of bilateral prophylactic nipple-sparing mastectomy in patients with high risk of breast cancer. Br J Surg. 2020 Sep;107(10):1307-1312. doi: 10.1002/bjs.11616. Epub 2020 May 20